A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011

NCT07295496 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Gout Flare

Interventions

DRUG: IBI3011
DRUG: IBI3011 Placebo

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.